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Platelet activating factor is produced during infectious peritonitis in
CAPD patients. Peritonitis, a frequent complication of continuous
ambulatory peritoneal dialysis (CAPD), is a model of inflammation
which provides the opportunity to recover the exudate fluid. To date,
various endogenous mediators (histamine, bradykinin, activated com-
plement factors, prostanoids) have been implicated in the mediation of
peritoneal inflammation and increased peritoneal permeability. In the
present study, a lipid compound with physicochemical and biological
characteristics similar to platelet activating factor (PAF) (1-0-alkyl-
2-acetyl-sn-glyceryl-3-phosphorylcholine) was extracted in significant
amounts from the dialysate of eight out of nine peritonitis episodes in
seven CAPD patients (Group A; 6771.4 3025.9 p, mean SEM at the
first exchange during peritonitis). The amounts of PAF recovered in the
first exchange dialysate from patients of Group A were linearly corre-
lated with the loss of albumin (y = —3157.64 + 9l.41x; r = 0.7394; N =
9; P <0.03) and number of leukocytes (y = 902.45 + l.52x; r = 0.7576
N = 9; P < 0.02). PAF was not detectable in the dialysate fluid from
patients of Group A after recovery. Twelve patients on CAPD who had
no past or present history of peritonitis (Group B) were used as
controls; no PAF (9 patients) or only minimal amounts (3 patients: 7.0
pM; 23.0 psi; 70.0 pM) of this mediator were detected. This is the first
direct demonstration of the local generation of PAF in a septic inflam-
matory reaction involving the peritoneal serosa in man. PAF produced
by various cell types (neutrophils, peritoneal macrophages, endothelial
cells) during peritoneal inflammation may contribute to the increased
permeability of the peritoneal vascular bed.
Platelet activating factor (PAF), initially recognized as a
mediator of anaphylaxis released by antigen-stimulated IgE-
sensitized rabbit basophils [1], belongs to a new class of lipid
chemical mediators, the acetylated alkyl phosphoglycerides [21,
and exerts a broad spectrum of diverse and potent biological
activities. Besides its activity on platelets [1], PAF promotes
the aggregation, chemotaxis and granule secretion of polymor-
phonuclear neutrophils (PMN) [3, 4] and monocytes [5]. PAF
enhances vascular and glomerular permeability leading to
hemoconcentration with extravasation of plasma proteins, ac-
cumulation of leukocytes, edema, vasoconstriction and vasodi-
lation [6, 7]. The injection of PAF into serosal cavities induces
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inflammation characterized by a rapid development of exudate
and by leukocyte migration [8]. Peritonitis, a complication of
continuous ambulatory peritoneal dialysis (CAPD) [9], a sub-
stitutive treatment for end-stage renal failure (ESRD) [10], is a
model of inflammation which provides the unique opportunity
to recover the exudate fluid. Vasoactive amines [11], pros-
tanoids [12] and activated complement compounds [13] were
detected in the peritoneal cavity and related to the enhanced
peritoneal permeability occurring during peritonitis.
The present study demonstrates for the first time a local
generation of PAF in a septic inflammatory reaction involving
the peritoneal serosa in man. PAF was extracted from the
peritoneal exudates of patients on CAPD and with clinical and
laboratory evidence of peritonitis. The levels of PAF were
correlated with the increase of peritoneal permeability.
Methods
Patients and controls
Nineteen patients (aged 40 to 79 years, 61.63 2.04 years,
mean sEM) undergoing CAPD for ESRD were studied (Table
I). Seven of these patients (Group A) were evaluated during
nine episodes of peritonitis and three to six weeks later when
they recovered. Twelve patients (Group B) who had no past or
present history of peritonitis were used as controls. The renal
residual creatinine clearance in Group A (2.21 1.34 mllmin)
was not significantly different from that of Group B patients
(2.87 0.91 ml/min; P > 0.5).
The causes of the underlying renal failure in Group A and B
patients are reported in Table 1. The criteria for including the
patients in the study were: absence of hypertensive state or
medically controlled hypertension, absence of other systemic
diseases—such as diabetes mellitus or autoimmune disease—
and CAPD for at least two months. In addition, patients with
peritonitis were included in Group A only when it was possible
to collect the first sample of dialysate (period I) after a six-hour
dwell time upon hospital admission.
Peritonitis was diagnosed on the basis of abdominal tender-
ness accompanied by an elevated leukocyte count (above
300/mm3) and/or positive dialysate culture [9].
Informed consent was obtained from all the patients included
in this study.
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Table 1. Characteristics of patients undergoing CAPD
Patient
no.
Age
years Sex Primary disease
BCE,.
mi/mm Infective agent
Clinical
symptom?
Months
on CAPD
Previous episodes
of peritonitis
Group A
b1
b2
3
4
5
6
7
66
66
54
54
60
66
66
62
69
F
F
M
M
F
F
F
.
Nephroangiosclerosis
.
Polycystic kidney
Chronic glomerulonephritis
Nephroangiosclerosis
Nephroangiosclerosis
Chronic pyelonephritis
Chronic pyelonephritis
1 3.95
I
t 3.91
1 0.79
I
t 0.68
0
10.63
0
0
0
Streptococcus Group D
.Klebs,ella Oxytoca
Pseudomonas Aeruginosa
.
Streptococcus Alpha-Hemolyticus
Staphylococcus Aureus
Escherichia coli
Staphylococcus Epidermidis
Candida Albicans
Negative
1 2
1,2
1 2
1,2,3
1,2,4
1,2,3
1
1,2
1,2,4
2
9
19
25
32
22
23
24
35
0
1
1
2
2
0
0
1
6
Group B
8
9
10
11
12
13
14
15
16
17
18
19
79
72
66
66
55
63
49
57
65
64
52
40
F
M
M
M
F
F
F
M
F
M
M
F
Nephroangiosclerosis 2.03
Nephroangiosclerosis 4.25
Interstitial nephropathy 0
Nephroangiosclerosis 11.01
Chronic pyelonephritis 1.25
Chronic glomerulonephritis 2.71
Chronic glomerulonephritis 0
Chronic pyelonephntis 6.10
Obstructive nephropathy 3.43
Chronic pyelonephritis 2,46
Polycystic kidney 1.26
Nephrectomy in pyonephrosis 0
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
0
0
0
0
0
0
0
0
0
0
0
0
7
5
46
15
61
44
49
28
3
14
7
22
0
0
0
0
0
0
0
0
0
0
0
0
a Clinical symptoms: I dialysate turbidity; 2 abdominal pain; 3 body temperature; 4 abdominal tenderness.b Patient no. I and no. 2 had a second episode of peritonitis.
Abbreviations are: BCr, blood creatinine clearance; M, male; F, female.
Dialysis technique
CAPD was performed with dialysis solutions containing
1.36% to 2.27% glucose concentration (Travenol, Deerfield,
Illinois, USA) employing four exchanges of 1.5 to 2.2 liters
dialysate daily.
Therapy of peritonitis
Therapy of peritonitis consisted of three rapid in-and-out
exchanges (1.0 liter of 1.36% glucose dialysis solution without
additives) followed by a six-hour dwell time with dialysis
solution containing 1 g cephalotin (Keflin, Eli Lilly & Co,
Indiana, USA) and 1.7 mg/kg body wt tobramycin (Nebicina®,
Eli Lilly & Co) [14]. The maintainance antibiotic therapy
(cephalotin 250 mg/liter, tobramycin 8 mg/I) [14] was continued
in uncomplicated peritonitis until the second dialysate culture
was negative (at about the 10th day of therapy).
Study in patients of Group A
Four samples of dialysate effluents after a six-hour dwell time
were sequentially collected during the first 24 hours: the first
drawing on hospital admission before the in-and-out exchanges
and the start of antibiotic therapy (period I, Table 2); the second
at the time of antibiotic administration in the dialysis solution
(period II); and the third and fourth in the following 12 hours
(periods III and IV). The fourth exchange was obtained only in
six patients. Three to six weeks later, after discontinuation of
antibiotic therapy, exchanges of dialysate were obtained after a
six hour dwell in complete absence of signs and/or symptoms of
peritonitis (Group A at recovery). Leukocytes were counted in
a Fuchs-Rosenthal chamber and PAF was extracted from 30 ml
of dialysate effluents. Dialysate net drainage volume was deter-
mined by subtracting the weight of the bag before infusion from
the bag after dialysate efflux. The ultrafiltration was calculated
by subtracting the volume of dialysate infused solution from the
dialysate net drainage volume. Furthermore, total serum pro-
teins and beta2-microglobulin (/32m), albumin (Alb), transferrin
(TRF), immunoglobulin G (IgG), alpha2-macroglobulin (s2m)
and immunoglobulin M (1gM) were evaluated in both dialysate
and serum from venous blood samples obtained before starting
antibiotic therapy.
In addition venous blood samples (5 ml) drawn at the hospital
admission were processed for extraction of PAF from plasma
[15].
Study in patients of Group B
The extraction of PAF was performed in 30 ml samples of the
dialysate effluents obtained after a six hour dwell. Total and
individual serum proteins were determined in both dialysate
and venous blood samples. Five ml samples blood were proc-
essed for PAF extraction from plasma [15]. In six patients of
this group, the remaining dialysate was collected in a sterile bag
and cephalotin (1 g) plus tobramycin (1.7 mg/kg body wt) were
added. Blood venous samples (20 ml) from each patient were
used to prepare purified PMN which were added to the dialy-
sate (final concentration 3500 28.73 cells/mm3) [3]. After
incubation at 37CC for 20 minutes the PMN dialysate suspension
was tested for the presence of PAF after extraction and
purification.
To evaluate whether the different concentrations of albumin
in the dialysate from Group B (30.0 4.4 mg/dl) that was lower
than that from Group A patients (108.6 23.0 mg/dl, period I)
may have affected the recovery of PAF, six patients of Group B
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were infused with 1.36% glucose dialysis solution supplemented
with 100 mg/dl of purified human albumin (Travenol), and the
presence of PAF was evaluated after a six hour dwell.
Chemical analysis and radioimmunoassay
A nephelometric method (Auto ICS, Beckmann Instruments,
Inc., Brea, California, USA) was used to quantify blood and
dialysate AIb, TRF, IgG, a2m and 1gM. 1gM and a2m were
measured in dialysates after 40-fold concentration in an Amicon
ultrafiltration apparatus with a PM-b membrane (cut off 10,000
daltons) [16]. f32m in serum and dialysate was determined by
radioimmunoassay (Pharmacia Diagnostics, Uppsala, Sweden)
[17]. Total serum protein, in both venous blood and dialysate
samples, were determined by Biuret method [12].
The loss of total and individual proteins of various molecular
weight, as a function of altered peritoneal permeability, was
expressed as the ratio dialysate/plasma protein concentration
(DIP) [12].
Purification and characterization of PAF
The effluent samples of the dialysate and plasmas were
extracted and purified by methods previously described for the
recovery of PAF from biological specimens [15, 18]. The
samples were acidified to pH 3.0 to 3.5 with I N HC1 to destroy
the acid-labile inhibitor of PAF [15]. Lipids were extracted by
1.9 vol of methanol. After one hour incubation at room temper-
ature, the precipitated proteins were removed by centrifugation
and 2 vol of chloroform, 0.1 vol methanol and 0.8 vol water
were added to the supernatant to effect phase separation [15].
The lower chloroform-rich phase was then subjected to thin
layer chromatography (TLC) on precoated silica gel plates
60F254 (Merck, Darmstad, FRG), using chloroform:methanol:
water 65:35:6 vollvollvol [15], as the solvent system. Subse-
quently, each plate was sectioned in 1 cm segments starting at
the origin, and the lipid of each fraction was extracted accord-
ing to Pinckard, Farr and Hanahan [15] and further character-
ized by its retention time on a high-performance liquid chroma-
tography apparatus (HPLC) (Beckman Instruments, Palo Alto,
California, USA) equipped with a jsPorasil column (Millipore
Chromatographic Div., Waters, Milford, Massachusetts, USA).
Elution was carried out with chloroform:methanol:water, 60:
55:5 vollvollvol at a flow rate of 1.0 mllmin [19]. Synthetic PAF
(Bachem Feinchemikalien AG, Switzerland), sphingomyelin
and lyso-2-phosphatidylcholine (Lyso-PC) (Sigma, Chemical
Co., St. Louis, Missouri, USA) were used as reference lipids.
The fractions were dried under N2, resuspended in 0.5 ml
Tris-buffered Tyrode's solution with 0.25% bovine serum albu-
min (BSA) (Pentex Fraction V, Miles Laboratories, Kankakee,
Illinois, USA) and bioassayed on washed rabbit platelets as
described below. The recovery of synthetic PAF was routinely
evaluated by mixing 15 ng of synthetic PAF (1-0-octadecyl-
2-acetyl-sn-glyceryl 3-phosphorylcholine, Bachem Feinchemi-
kalien AG, Bubendorf, Switzerland [2] or 0.1 pCi of [3H] PAF
(120 Ci/mmol) with 30 ml of dialysis solution, followed by
extraction, TLC and HPLC [19]. The recoveries of synthetic
PAF and of synthetic [3H] PAF were evaluated as biological
activity (88.0 3.8%) and radioactivity (93.2 3.1%), respec-
tively. All samples eluted from the HPLC column and active on
washed rabbit platelets were characterized as containing PAF
by comparison with synthetic PAF and with PAF derived from
IgE sensitized rabbit basophils [15] according to the following
criteria: 1) chromatographic pattern on TLC using chloroform-
methanol-water (65:35:4 vollvollvol or 65:35:6 vol/vol/vol) as a
solvent, with migration between lyso-PC and sphingomyelin
[15]. 2) PAF was also defined by physicochemical characteris-
tics such as inactivation by strong bases, resistance to acid and
weak basic conditions [15], and inactivation by phospholipase
A2 but not lipase Al [20]. The methods used have been
described in detail in previous papers [18, 19]. In brief, base
catalyzed methanolysis was performed in 2 ml 0.03 N NaOH
dissolved in methanol with an incubation of five minutes at
22°C, followed by acidification of the samples to pH 6.5 0.1
with 3 N HC1. PAF was subjected to acidic treatment for three
hours at 22°C. The samples were dissolved in 1 ml chloroform-
methanol (9:1, vol/vol) to which 1 vol 0.03 N HC1 was added. To
test the effect of weak basic conditions, PAF dissolved in 1 ml
chloroform-methanol (9:1, vol/vol) was reacted with 0.5 vol
ammonium hydroxide 28% for 30 minutes at 22°C under stir-
ring, followed by acidification to pH 6.5 0.1 with 1 N HCI.
After the various chemical treatments, the lipids were extracted
according to Bligh and Dyer [21]. The treatment with different
lipases was performed on dried samples. The assay mixture for
phospholipase A2 contained 1 ml Tris-buffered 150 mM NaCI,
pH 8.0, containing 10 mri CaCI,. Before the addition of 0.03 mg
phospholipase A2, the mixture was sonicated (100 W, 5 mm in
ice bath). The reaction was performed at 37°C for one hour.
Lipase Al hydrolysis was accomplished by sonicating the
sample (100 W, 5 mm, in ice bath) in 1 ml borate buffer 0.1 M,
pH 6.5 containing 10 mi CaC12, 1 mrvi deoxycholate, and 0.4%
BSA, and then incubating the mixture with 0.2 mg of the
enzyme for 22 hours while stirring. After the lipase treatment,
the lipids were extracted according to Bligh and Dyer [21]. In
control experiments, treatment of [3H] PAF (0.5 zCi) with
phospholipase A2 or base-catalyzed methanolysis hydrolyzed
94 to 99% of [3H] PAF to lyso-PAF [19]. Lipase Al as well as
acidic and weak basic conditions did not cause significant
hydrolysis of [3H] PAF (0 to 6%) [19]. After base-catalyzed
methanolysis or phospholipase A2 treatment, lipids were acetyl-
ated in the presence of 1 ml of acetic anhydride and 1 ml
pyridine for 20 hours at room temperature [22]. After lipid
extraction as described above, the biologically active material
was tested on washed rabbit platelets and compared with
untreated controls. 3) PAF was also characterized by ability to
induce platelet aggregation independently from both ADP and
arachidonic acid thromboxane A2-mediated pathways [23]. The
specificity of platelet aggregation was inferred from the inhibi-
tory effect of platelet pretreatment (30 seconds at 37°C under
continuous stirring at 900 rpm) with 5 jiM of a PAF receptor
antagonist CV-3988 (Takeda Chemical Industries, Kyoto, Ja-
pan) [24]. CV-3988 was first dissolved in saline, heated for five
minutes at 60°C, cooled at room temperature and used within
one hour.
PAF assay
After extraction and purification by TLC and HPLC, PAF
was quantitated by aggregation of washed rabbit platelets in the
presence of 1 jiM indomethacin (Sigma Co.) which inhibits
cyclooxygenase and of creatine phosphate (312.5 jsglml)/creat-
mine phosphokinase (152.5 jiglml) enzymatic system (Sigma
Co.) which converts ADP to ATP, thus blocking the arachi-
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Table 2. Biochemical data in patients with (Group A) and without (Group B) peritonitis
Groups
Ultra-
filtration
(ml/6h)
Total proteins
mg/dl
/32-microglobulin
mg/liter
s d
Albumin
mg/dl
s d s d
Group A (7 patients)
Period Episodes of
peritonitis
1 9 —2l1.1'" 6350.0 347 '34b 32555b.d 1086b,d
II 9 —222.2 1259b.e 533 717b.d
III 9 556b 1670b,d
7 198•5b4 775b 1051b,d
At recoverya (5 patients) 228.6 6647.7 67.6 28.4 3.41 3764.3 44.4
(no. 7 exchanges) 14.2 171.4
Group B (12 patients)
Only dialysate 68.7 6816.6 58.2 34.4 4.96 4015.0 30.0
(no. 12 exchange) 125.7 173.9
Dialysate PMN —37.5 6683.3 59.2 35.7 6.0 3986.6 28.0
(3500 100/mm3) ±76.1 ±224.2 ±3.8 ±8.2 ±1.3 ±316.3 ±5.0
(no. 6 exchanges)
Dialysate ± albumin 8.33" 6850.0 220.0' 38.3 49" 39633h 161.6
(100 mg/dl) ±58.3 ±117.6 ±25.1 ±4.4 ±1.0 ±95.3 ±11.8
(no. 6 exchanges)
a Group A patients studied during peritonitis episodes and at recovery are defined in the legend of Fig. 1.
The Student's t-test was evaluated between: Group A during peritonitis versus Group A at recovery ("P < 0.05; C < 0.001); Group A during
peritonitis versus Group B only dialysate ("P < 0.05; C C 0.001); Group A at recovery versus Group B only dialysate (1P C 0,05; gp < 0.001);
Group B dialysate ± albumin versus Group A period 1 (t < 0.05; 'P < 0.001); Group B dialysate + albumin versus Group B only dialysate (ip
<0.001).
Abbreviations are: s, serum; d, dialysate.
donic acid- and ADP-dependent platelet aggregation, respec-
tively [25]. The amount of PAP was expressed in M and
calculated over a calibration curve of synthetic PAP con-
structed for each test [251.
Statistical analysis
The patients underwent consecutive measurements during
peritonitis and peritonitis-free periods. The data were evaluated
by Student's t-test and linear regression analysis. Values were
given as means ± SEM. P values c 0.05 were considered
statistically significant.
Results
Table 1 summarizes the characteristics of the patients se-
lected for this study. In patients of Group A, four out of nine
episodes of peritonitis were caused by gram-positive microor-
ganisms (Staphylococcus aureus and epidermidis, Streptococ-
cus Group D and Alpha-Hemolyticus), three episodes by
gram-negative (Kiebsie/la Oxytoca, Escherichia coli and Pseu-
domonas Aeruginosa), and one episode by fungi (Candida
Albicans). Negative bacterial cultures were obtained in one
episode. Patients of Group B were peritonitis-free (Table 1).
The residual creatinine clearances of patients in Group A and B
were comparable (Table 1).
A compound exhibiting physicochemical and biological prop-
erties similar to PAF was identified in eight out of nine
peritonitis episodes developed by the seven patients of Group
A. Figure 1 shows that the highest amounts of PAP were
detectable in the first exchange of the dialysate (period I) in
spite of the large variability in the amount of PAF extracted
from the dialysate of different patients and of different ex-
changes in the same patient. The production of PAF was
unrelated to the renal status of the patients. The amounts of
PAF progressively declined in the following exchanges and
PAF became undetectable in all the patients studied after
recovery. In patients of Group B, used as controls, PAF was
not detectable (9 patients) or was detectable only in minimal
amount (3 patients). In the three patients with detectable PAP
(patient no. 8 : 7.0 pM; patient no. 11: 23.0 pM; patient no. 13:
70 pM) significant differences concerning leukocytes and dialy-
sate protein losses were not observed, as compared to the nine
patients negative for PAP extraction. When purified autologous
PMN were added in vitro to the dialy sate of patients of Group
B in a number comparable to the one found in patients with
peritonitis (Group A), the amounts of PAF extracted from the
dialysate (Fig. 1) did not significantly increase. Likewise, the
addition of albumin to the dialysate of six patients of Group B,
in concentration comparable to that detected during peritonitis
(Group A, period I), did not increase the amount of extractable
PAF (Fig. 1). PAF was never detected in the dialysate effluents
from patients of Group A evaluated three to six weeks after the
episodes of peritonitis.
No detectable amounts of PAF were found in plasmas from
patients with peritonitis (Group A) and controls (Group B).
PAP present in the dialysates had physicochemical and
biological characteristics similar to those of PAP released from
IgE sensitized rabbit basophils and of synthetic PAP: 1) it had
the same migratory properties on TLC (Rf = 0.21, with a
solvent system chloroform:methanol:water 65:35:6 vol/vollvol)
between lyso-PC (Rf = 0.11) and sphingomyelin (Rf = 0.29)
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Table 2. Continued
Transferrin IgG a2-macroglobulin 1gM
mg/dl mg/dl mg/dl mg/dl
s d s d s d s d
234.5" 629b 1254.4 215b 238.5 387b,d 145.1 220b,d
4.84"
5.92"
6.63"
16.7
225b
19.3
304C.e
335b.
379b,e
181b,d
256b,d
159"
234.3 2.29 1310.3 11.4 228.4 1.03 197.8 0.91
63.7
28I.6f 4.23 1095.0 13.4 1331g 049f 143.0 0.74
±10.3 ±0.6 ±114.8 ±2.3 ±6.7 ±0.06 ±20.5 ±0.1
275.3 3.63 1181.8 12.8 142.2 0.46 137.5 0.52
±19.8 ±0.9 ±191.6 ±3.8 ±8.5 ±0.1 ±35.6 ±0.1
292.0" 5.50 113I.2 13.3 139.6k 054h 133.5 0.60"
±22.6 ±0.8 ±150.4 ±2.0 ±22.2 ±0.1 ±28.4 ±0.1
a Group A patients studied during peritonitis episodes and at recovery are defined in the legend of Fig. 1.
The Student's f-test was evaluated between: Group A during peritonitis versus Group A at recovery (bp < 0.05; P < 0.001); Group A during
peritonitis versus Group B only dialysate ("P < 0.05; P < 0.001); Group A at recovery versus Group B only dialysate (p < 0.05; S < 0.001);
Group B dialysate + albumin versus Group A period I (hp < 0.05; 'P < 0.001); Group B dialysate ÷ albumin versus Group B only dialysate (JP
<0.001).
Abbreviations are: s, serum; d, dialysate.
[15]. No PAF activity was detected in other TLC fractions.
Using a solvent system with different pH (neutral, acid and
basic) the Rf of PAF extracted from peritoneal fluid was similar
to synthetic PAF, indicating its neutral nature. However, using
solvent system with different polarity (chloroform-methanol-
water 65:35:4 vol/vol/vol) the Rf of PAF present in the dialysate
as well as that of synthetic PAF were significantly changed (Rf
= 0.10), indicating the polar lipid nature of the biologically-
active material extracted [15]. By HPLC, PAF present in the
dialysate coeluted with synthetic PAF with a Rt of 20 minutes
[19]. 2) PAF activity was destroyed after base-catalyzed meth-
anolysis (0% to 1% recovered activity) or after treatment with
phospholipase A2 (0% to 4.3% recovered activity), indicating
the presence of an ester linkage at sn-2 [15, 20, 25]. The
treatment with lipase Al did not inhibit the PAF activity,
suggesting the presence of an ether bond at sn-i (98 to 100%
recovered activity) [20, 25]. The presence of an alkyl ether bond
at sn-i was unlikely, because acidic condition had no effect on
PAF activity (94% to 100% of recovered activity) [15]. Finally,
treatment with a weak base suggested that the biologically
active material did not contain ionizable groups [15]. After
base-catalized methanolysis or inactivation with phospholipase
A2, treatment with acetic anhydride restored (82 to 91% of
recovered activity) the biologic activity. 3) It induced aggrega-
tion of washed rabbit platelets by an ADP- and arachidonate-
independent pathway. This aggregation was inhibited by CV-
3988, a specific PAF receptor antagonist [24].
Figure 2 shows that the dose-response curves for synthetic
PAF and TLC-purified PAF of the seven patients with perito-
nitis are superimposable. As shown by the narrow standard
error of the mean, PAF activity was on a molar basis equivalent
in all seven patients with peritonitis.
The amounts of PAF detected in all periods (from Ito IV) in
patients with peritonitis (Group A) linearly correlated with
leukocyte counts (y = 570.60 + l.3869x; r = 0.6864; P <
0.0005) and with albumin concentration in the dialysate (y =
—1582.72 + 77.8184; r = 0.5076; P < 0.005). In patients of
Group A in period I, a significant linear correlation was found
between the amounts of PAF, leukocyte counts (y = 902.45 +
l.52x; r = 0.75762; P < 0.02) and albumin concentrations (y =
—3157.64 + 91.40x; r = 0.73946; P <0.03). In patients of Group
A in period II (y = 313.24 + l.78x; r = 0.75556; P < 0.02) and
in period III (y = 871.51 + i.24x; r = 0.75193; P < 0.02) a
significant linear correlation existed only between PAF and
leukocytes but not between PAF and albumin concentrations.
In patients of Group A in period IV, Group A at recovery and
Group B, no significant correlation was found between PAF and
leukocytes, and between PAF and albumin concentrations. No
significant differences in dialysate leukocyte count (Fig. 1), total
proteins and individual proteins (except for TRF and a2m) were
found between patients of Group A after recovery and patients
of Group B (Table 2).
Peritonitis was associated with decreased ultrafiltration and
with loss of total proteins and individual proteins of various
molecular weight, as summarized in Table 2. During peritonitis
a significant increase in peritoneal permeability was observed
for all proteins investigated, independently of their molecular
weight. The loss of total dialysate proteins reached 160 ± 15.5
mgldl (range, 13 to 389 mgldl) during peritonitis and decreased
to 67.5 ± 14.2 mgldl (range, 22 to 139 mgldl) in the exchanges
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and with PAF extracted and purified from peritoneal dialysate of 7
patients with peritonitis (D—D), of2 to 5 1O washed rabbit platelets
as described in [25]. Data are given as mean SEM.
Fig. 1. PAF release (lJ), dialysate leukocyte count () and albumin
concentration () in patients with peritonitis (Group A) and in controls
(Group B). Group A includes 7 patients with a total of 9 episodes of
peritonitis. Two patients (no. I and no. 2, Table 1) had a second episode
of peritonitis with a interval of 7 and 6 months, respectively. PAP
extracted from dialysate during the interval of time between the two
episodes of peritonitis was 0 in both patients. Values obtained in period
I, II and III of Group A patients were calculated on 9 episodes of
peritonitis. Values calculated for period IV are derived from 7 episodes
of peritonitis studied in 6 patients. Recovery was evaluated only in 5
patients for a total of 7 exchanges, since one patient died (no. 3) and
another (no. 6) was switched to hemodialysis for development of a
fungal peritonitis. The Students' t-test was used to evaluate for PAF,
leukocyte count and albumin concentration between Group A during
peritonitis (Period I, II, III and IV) versus Group A at recovery (* <
0.05; ** < 0.001), Group A during peritonitis (Period I, II, Ill and IV)
versus Group B only dialysate (tP < 0.05; liP < 0.001), Group A at
recovery versus Group B only dialysate (P < 0.05), Group B dialysate
+ albumin versus Group A period I (IP < 0.001), Group B dialysate +
albumin versus Group B only dialysate (JP < 0.001) and Group B
dialysate + PMN versus Group B only dialysate (lIP < 0.001), Where no
symbols were added (between the performed Student t-test specified
above), no significant difference was found.
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Fig. 3. Ratio of dialysate/plasma protein concentration (DIP) in Group
A patients during peritonitis (period I, closed squares) and after
recovery (closed circles). The DIP ratio was used to define peritoneal
permeability [121 to proteins with different molecular weight. The
values are plotted on a logarithmic scale; they were determined as the
D/P ratio for each individual patient, and then averaged to obtain the
mean SEM. The D/P ratios during peritonitis period I were :p2m =
0,209178 0.026585; AIb = 0.034522 0.008187; TRF 0.026256
0.006229; IgG = 0.017089 0.002479; n2m 0.015756 0.003554; 1gM
= 0.0145589 0.006337. The D/P ratios after recovery were: 32m =
0,117214 0.009605; AIb = 0.01 1957 0.002068; TRF = 0,009700
0.001055; IgG = 0.008829 0.001099; s2m = 0.004443 0.000713; 1gM
0.005300 0.001560. Abbreviations are: /32m, beta-2-microglobulin;
AIb, albumin; TRF, transferrin; IgG, Immunoglobulin G; a2m, alpha-
2-macroglobulin; 1gM, immunoglobulin M.
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obtained three to six weeks later (Table 2), when the patients
recovered. During the episodes of peritonitis, the DIP ratio
increased for all proteins investigated and led to a parallel shift
of the exponential permeability profile obtained in the absence
of inflammation (Fig. 3).
Discussion
Peritonitis, a relatively frequent complication of CAPD, is an
inflammatory response of the peritoneal membrane to infective
agents (bacteria and fungi), During peritoneal inflammation,
there is an increased permeability to serum proteins. Endoge-
nous mediators of inflammation such as histamine [111, brady-
kinin [11], activated complement components [13], and pros-
tanoids of the I and E types [12] are considered as likely
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candidates in the alteration of peritoneal capillaries and
venules.
In the present study, a lipid compound with physicochemical
and biologic characteristics similar to l-0-octadecyl-2-acetyl-
sn-glyceryl-3-phosphorylcholine (PAF) was extracted in signif-
icant amounts in eight out of nine CAPD peritonitis episodes in
CAPD patients (Group A). The amounts of PAF in the dialysate
fluid were linearly correlated with the protein loss in the
dialysate. A parallel shift in the exponential profile of perme-
ability to proteins of various molecular weight (132m, AIb, TRF,
IgG, a2m and 1gM) was also found. In Group A patients, PAF
was detectable in significant amounts only during peritonitis.
Three to six weeks after the episodes of peritonitis PAF was no
longer detectable.
In Group B patients, who had no past or present episodes of
peritonitis, and who were used as controls, PAF was undetect-
able (9 patients) or detectable only in minimal amounts (3
patients). In addition, the increased amounts of PAF recovered
in patients with peritonitis could not be abscribed to the
increased number of leukocytes or to the increased albumin
concentration in the dialysate. In fact, the addition of purified,
unstimulated PMN or albumin to the dialysate of control
patients (Group B) did not significantly increase the amounts of
extractable PAF. These results suggest that activation of in-
flammatory cells by some mechanism operating in the dialysate
is required for the production of PAF in patients with peritoni-
tis. In addition, the presence of PAF in patients with peritonitis
cannot be ascribed to an increased concentration of albumin
acting as a PAF carrier. It is conceivable that the amounts of
PAF generated during peritonitis may be underestimated be-
cause of its relative insolubility in aqueous media, its binding to
the surface of peritoneal cells, and inactivation by the specific
plasma PAF acetylhydrolase [26]. On the other hand, PAF was
not detected in plasmas from patients with peritonitis. This may
depend either on the presence of plasma proteinase inhibitors
that impair PAF synthesis by inflammatory cells [271 or on the
plasma-specific PAF acetylhydrolase that degrades the PAF
molecule, thus abolishing its biological activity [261. While
plasma PAF acetylhydrolase is carried by high molecular
weight lipoproteins, plasma proteinase inhibitors such as al-
proteinase inhibitor (al-PI), a protein with a molecular weight of
50,000 daltons, may pass the peritoneal barrier and may block
PAF synthesis. However, the presence of PAF during perito-
nitis may suggest that for PAF to be synthetized and released,
inactivation of cd-PI may be required [27]. Such inactivation
was observed in rheumatoid synovial fluid, where al-PI con-
taining methionine sulphoxide residues was recovered [28].
It is suggested that in acute peritonitis generation of products
from the enhanced oxidative metabolism [29] may oxidate al-PI
that would not inhibit PAF synthesis by inflammatory cells [27].
One can only speculate on which cells are responsible for the
production of PAF. Three are the likely candidates: I) PMN
that are known to produce PAF when activated with inflamma-
tory stimuli such as C5a, cationic proteins, tumor necrosis
factor (TNF) and during phagocytosis [3, 4]; 2) peritoneal
macrophages that have been shown to produce PAF when
exposed to phagocytic stimuli [30], bacterial endotoxins [31]
and TNF [32]; and 3) the endothelial cells which are able to
synthetize PAF [25, 33] when stimulated by mediators such as
interleukin I [34] and TNF [32].
At present it is unknown whether mesothelial cells are
capable to generate PAF. However, such possibility cannot be
ruled out since they share a common embryogenic origin with
the endothelial cells [35].
Since PAF is 1,000 to 10,000 times more potent than hista-
mine in increasing vascular permeability [36], it is conceivable
that PAF produced during peritoneal inflammation may contrib-
ute to increase the permeability of the peritoneal membrane. In
addition, PAF may have a direct vascular effect or act through
secondary mediators released from recruited inflammatory cells
(PMN, macrophages and platelets) [37].
The direct demonstration that PAF is responsible for the
increased peritoneal permeability can not be achieved in hu-
mans where PAF or PAF receptor antagonists can not be
injected intraperitoneally. However, in experimental animals it
has been shown that PAF plays an important role in inducing
enhanced permeability and inflammation in serosae [38, 39].
Further studies are needed to clarify the role of PAF in the
physiopathology of the peritoneal inflammation occurring in
patients treated with CAPD and to evaluate the therapeutic
potential of specific PAF receptor antagonists when they are
available for clinical research.
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